Natera, Inc. NTRA
311.98 USD -8.41 (-2.62%)
At closeNov 11, 2026, 5:34 AM EST
314.00 +2.02 +0.65%
Pre-market · Nov 11, 5:34 AM ET
307.08 Day range 323.73
181.00 52-week range 437.41
- YTD
- +36.18%
- 1 year
- +50.92%
News
benzinga.com Natera Enters Into Clinical Collaboration Agreement With Incyte For New Phase II Study In Colorectal Cancer Trial designed to improve outcomes through Signatera™-guided Treatment on MRD (TOMR), identifying high-risk patients for curative-intent treatmentNatera, Inc. (NASDAQ:NTRA), a global leader in…
zacks.com Natera Q3 Earnings Call Highlights $6B Target & Raised 2026 Outlook NTRA targets $6B in revenues by 2029 as Signatera testing surges, reimbursement expands and higher investments support its long-term growth strategy.
zacks.com NTRA Q3 Loss Wider Than Expected, Revenues Beat, '26 Sales View Up Natera???s Q3 revenues jump 34.1%, beating estimates, while a wider-than-expected loss and surging oncology test volumes shape its raised 2026 sales outlook.
benzinga.com Baird Maintains Outperform on Natera, Lowers Price Target to $403 Baird analyst Catherine Ramsey maintains Natera (NASDAQ:NTRA) with a Outperform and lowers the price target from $458 to $403.
defenseworld.net Natera, Inc. $NTRA Stock Holdings Lessened by Candriam S.C.A. Candriam S.C.A. cut its stake in shares of Natera, Inc. (NASDAQ: NTRA) by 1.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm…
defenseworld.net Natera (NASDAQ:NTRA) Insider Sells $1,401,003.63 in Stock Natera, Inc. (NASDAQ: NTRA - Get Free Report) insider Solomon Moshkevich sold 3,419 shares of the firm's stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of…- defenseworld.net Natera (NASDAQ:NTRA) Insider Sells $1,401,003.63 in Stock Natera, Inc. (NASDAQ: NTRA - Get Free Report) insider Solomon Moshkevich sold 3,419 shares of the firm's stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of…
defenseworld.net Natera (NASDAQ:NTRA) CEO Sells $1,565,251.80 in Stock Natera, Inc. (NASDAQ: NTRA - Get Free Report) CEO Steven Chapman sold 3,801 shares of Natera stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $411.80,…
seekingalpha.com Natera, Inc. (NTRA) Q3 2026 Earnings Call Transcript Natera, Inc. ( NTRA ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - CEO & Director Solomon Moshkevich - President of…
benzinga.com JP Morgan Maintains Overweight on Natera, Lowers Price Target to $405 JP Morgan analyst Casey Woodring maintains Natera (NASDAQ:NTRA) with a Overweight and lowers the price target from $460 to $405.
benzinga.com Natera Stock Plummets After Mixed Q3 Financials Natera Inc. (NASDAQ:NTRA) shares are plunging Friday after reporting mixed third-quarter results, with revenue and guidance beating estimates while the loss per share came in wider than analysts…
benzinga.com Natera Stock Plummets After Mixed Q3 Financials Natera shares are plunging Friday after mixed Q3 results, as a wider-than-expected loss offset revenue and guidance that topped estimates.
benzinga.com If You Invested $100 In Natera Stock 10 Years Ago, You Would Have This Much Today Natera (NASDAQ:NTRA) has outperformed the market over the past 10 years by 27.7% on an annualized basis producing an average annual return of 40.73%. Currently, Natera has a market capitalization of…
benzinga.com Evercore ISI Group Maintains Outperform on Natera, Lowers Price Target to $400 Evercore ISI Group analyst Daniel Markowitz maintains Natera (NASDAQ:NTRA) with a Outperform and lowers the price target from $468 to $400.
benzinga.com DraftKings Posts Downbeat Q3 Results, Joins Atlassian, Natera And Other Big Stocks Moving Lower In Friday’s Pre-Market Session Stock futures mixed as DraftKings plunged 21% after earnings missed estimates and FY26 guidance was cut; several other stocks also fell premarket.
marketbeat.com What Natera (NTRA) Said on Its Q3 Earnings Call Natera NASDAQ: NTRA raised its full-year revenue forecast after reporting a 34% increase in third-quarter revenue, as demand for its cancer-monitoring tests grew and the company announced a change in…
seekingalpha.com Allspring Growth Fund Q3 2026 Performers And Detractors During the third quarter, Natera achieved record results. Shares advanced during the quarter as Twilio's voice platform was recognized as a backbone for agentic voice agents. Carpenter Technology is…
seekingalpha.com Alger Concentrated Equity ETF Q3 2026 Portfolio Update The Alger Concentrated Equity ETF underperformed the Russell 1000 Growth Index during the third quarter of 2026. Microsoft Corporation, Natera, Inc., and Meta Platforms Inc were among the top…
benzinga.com Natera Q3 2026 Earnings Call Transcript Natera (NASDAQ:NTRA) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide real-time access…
benzinga.com Natera Q3 EPS $(0.42) Misses $(0.29) Estimate, Sales $793.981M Beat $704.901M Estimate Natera (NASDAQ:NTRA) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.29) by 44.83 percent. This is a 34.38 percent increase over losses of $(0.64)…- benzinga.com Natera Raises FY2026 Sales Guidance from $2.850B-$2.910B to $3.005B-$3.035B vs $2.907B Est Natera (NASDAQ:NTRA) raises FY2026 sales outlook from $2.850 billion-$2.910 billion to $3.005 billion-$3.035 billion vs $2.907 billion estimate.
businesswire.com Natera Announces Leadership Transition AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, today announced that Solomon Moshkevich has been appointed Chief Executive…
businesswire.com Natera Reports Third Quarter 2026 Financial Results AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30,…
businesswire.com Signatera™ Monitoring During First-Line Immunotherapy Showed ctDNA Clearance is Associated with Long-Term Survival Across Four Metastatic Cancers AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced it will present important new Signatera data at the Society for…
benzinga.com Toyota, ConocoPhillips On Deck Thursday As Auto Demand, Oil Prices Face Test Toyota Motor headlines Thursday’s reports, with investors weighing the automaker’s earnings outlook against a stock still well below its 52-week high. ConocoPhillips, Sony Group, Parker Hannifin and…
businesswire.com Signatera™ in Head and Neck Cancer: Three New Publications Demonstrate Strong Clinical Performance and Actionability AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced three peer-reviewed publications in npj Precision Oncology, JAMA…
defenseworld.net Aware Super Pty Ltd as trustee of Aware Super Buys 16,018 Shares of Natera, Inc. $NTRA Aware Super Pty Ltd as trustee of Aware Super bought a new stake in Natera, Inc. (NASDAQ: NTRA) during the undefined quarter, according to the company in its most recent Form 13F filing with the…
benzinga.com Earnings Volatility Watch: 10 Stocks Are Set to Swing More Than 10% This Week Ten stocks carry implied earnings moves above 10% next week, led by Moderna and AppLovin. Five are tech names hit in Friday's chip rout.
benzinga.com Benzinga's 'Stock Whisper' Index: Five Stocks Investors Secretly Monitor But Don't Talk About Yet The Stock Whisper Index is a market indicator highlighting stocks that are attracting heightened interest from traders and investors over the last trading week.
benzinga.com Natera, Shake Shack, eBay And More On CNBC’s ‘Final Trades’ CNBC Final Trades: Sechan picked eBay, Simpson Natera, Thomas COWZ ETF and Brown Shake Shack; all four gained Thursday.
benzinga.com BTIG Maintains Buy on Natera, Raises Price Target to $430 BTIG analyst Mark Massaro maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $320 to $430.
benzinga.com Natera Highlights New Signatera Genome Assay Data At ESMO 2026, With ctDNA Dynamics Predictive Of Survival Outcomes In Bladder Cancer Natera’s oncology portfolio featured in 25 ESMO abstracts including 9 oral presentations, with publications in Nature Medicine and ESMO OpenNatera, Inc. (NASDAQ:NTRA), a global leader in cell-free…
benzinga.com $100 Invested In Natera 5 Years Ago Would Be Worth This Much Today Natera (NASDAQ:NTRA) has outperformed the market over the past 5 years by 17.81% on an annualized basis producing an average annual return of 28.94%. Currently, Natera has a market capitalization of…- benzinga.com Canaccord Genuity Maintains Buy on Natera, Raises Price Target to $500 Canaccord Genuity analyst Kyle Mikson maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $375 to $500.
- benzinga.com Morgan Stanley Maintains Overweight on Natera, Raises Price Target to $435 Morgan Stanley analyst Tejas Savant maintains Natera (NASDAQ:NTRA) with a Overweight and raises the price target from $355 to $435.
- benzinga.com TD Cowen Maintains Buy on Natera, Raises Price Target to $480 TD Cowen analyst Dan Brennan maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $340 to $480.
- benzinga.com Natera, TransCode Therapeutics Partnering To Support Enrollment For TransCode’s Phase 2a Study Of TTX-MC138 In Participants With Colorectal Cancer Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based…
benzinga.com Natera Reports Q2 2026 Results: Full Earnings Call Transcript On Thursday, Natera (NASDAQ:NTRA) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call…